FCM
Farallon Capital Management Portfolio holdings
AUM
$17.7B
1-Year Est. Return
25.69%
1 Year Est. Return
+25.69%
AUM
$17.7B
AUM Growth
-$4.09B
(-19%)
Holding
169
Top Buys
| 1 | +$323M | |
| 2 | +$235M | |
| 3 | +$185M | |
| 4 |
Wabtec
WAB
|
+$180M |
| 5 |
Hims & Hers Health
HIMS
|
+$144M |
Top Sells
| 1 | +$3.4B | |
| 2 | +$804M | |
| 3 | +$553M | |
| 4 |
Liberty Broadband Class C
LBRDK
|
+$421M |
| 5 |
ANSS
Ansys
ANSS
|
+$350M |
Sector Composition
| 1 | Healthcare | 45.75% |
| 2 | Technology | 15.89% |
| 3 | Financials | 12.88% |
| 4 | Communication Services | 6.89% |
| 5 | Industrials | 6.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
151
Janux Therapeutics
JANX
$1.01B
| – | – |
-48,000
|
|
||
152
Liberty Broadband Class A
LBRDA
$6.63B
| – | – |
-58,215
|
|
||
|
153
Liberty Broadband Class C
LBRDK
$6.65B
| – | – |
-4,274,445
|
|
||
154
Eli Lilly
LLY
$908B
| – | – |
0
|
|
||
|
PARA
155
DELISTED
Paramount Global Class B
PARA
| – | – |
-1,346,151
|
|
||
156
Invesco S&P 500 Equal Weight ETF
RSP
$74.8B
| – | – |
0
|
|
||
|
SAGE
157
DELISTED
Sage Therapeutics
SAGE
| – | – |
-42,800
|
|
||
158
SPDR S&P 500 ETF Trust
SPY
$701B
| – | – |
-5,500,000
|
|
||
|
SWTX
159
DELISTED
SpringWorks Therapeutics
SWTX
| – | – |
-5,000
|
|
||
|
THRD
160
DELISTED
Third Harmonic Bio
THRD
| – | – |
-15,361
|
|
||
161
United Therapeutics
UTHR
$20.8B
| – | – |
-1,000
|
|
||
|
VERV
162
DELISTED
Verve Therapeutics
VERV
| – | – |
-3,612,000
|
|
||
|
VRNA
163
DELISTED
Verona Pharma
VRNA
| – | – |
-1,810,000
|
|
||
164
Voyager Therapeutics
VYGR
$244M
| – | – |
-715,000
|
|
||
165
Full Truck Alliance
YMM
$11.8B
| – | – |
-1,550,598
|
|
||
|
BBOT
166
BridgeBio Oncology
BBOT
$891M
| – | – |
-600,000
|
|
||
|
LTM
167
LATAM Airlines Group S.A.
LTM
$14.8B
| – | – |
-318,092
|
|